CCC
LLY icon

Crescent Capital Consulting’s Eli Lilly LLY Stock Holding History

Crescent Capital Consulting’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$5.4M Buy
19,548
+1,807
+10% +$458K 0.89% 30
2021
Q3 		$4.1M Sell
17,741
-82
-0.5% -$20.2K 0.75% 34
2021
Q2 		$4.09M Sell
17,823
-207
-1% -$41.6K 0.77% 34
2021
Q1 		$3.37M Buy
18,030
+2,817
+19% +$551K 0.74% 41
2020
Q4 		$2.57M Buy
+15,213
New +$2.27M 0.66% 43

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Crescent Capital Consulting's LLY Position: Q4 2021 in Review

Crescent Capital Consulting increased its Eli Lilly (LLY) stake by 10% in Q4 2021, buying an estimated $458K and bringing the position to 19,548 shares worth $5.4M. The position accounts for 0.89% of the portfolio, ranked #30.

Crescent Capital Consulting first reported a position in LLY in Q4 2020 and has held it in 5 quarters since. 2,303 funds tracked by Wall St. Rank hold LLY as of Q4 2021.

  • Crescent Capital Consulting held 19,548 shares of Eli Lilly worth $5.4M as of Q4 2021.
  • Crescent Capital Consulting bought 1,807 Eli Lilly shares in Q4 2021, an estimated $458K.
  • Eli Lilly made up 0.89% of Crescent Capital Consulting's portfolio in Q4 2021, its #30 holding.
  • Crescent Capital Consulting first reported a position in Eli Lilly in Q4 2020 and has held it in 5 quarters since.
  • 2,303 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.